Cerenome
Clinical trials sponsored by Cerenome, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A multicenter phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (Rhenium-186 NanoLiposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases Results expected Oct 2026 (estimated)
-
A Two-Part, phase 1/2a trial to determine the maximum tolerated dose, safety, and tolerability of rhenium (186Re) obisbemeda (Rhenium-186 NanoLiposome, 186RNL) delivered via convection enhanced delivery (CED) in supratentorial recurrent, refractory, or progressive pediatric ependymoma and High-Grade glioma (HGG)
Recruiting nowPediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL). Phase 1 of the study will look to determine the maxi…
Phase 1 • Sponsor: Cerenome
Last updated Sep 09, 2026 17:00 UTC
-
A multicenter phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (Rhenium-186 NanoLiposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases
Recruiting nowThis is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptom…
Phase 1/2 • Sponsor: Cerenome
Last updated Sep 09, 2026 17:00 UTC